Drug Profile
Research programme: JNK-targeting molecules - Celgene
Alternative Names: CC-359; JNK-359; JNK-9359Latest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Cancer; Cerebral ischaemia; Diabetes mellitus; Epilepsy; Fibrosis; Neurodegenerative disorders; Reperfusion injury
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA